Dr. Oliver Zimmer
Wissenschaftlicher Mitarbeiter, Schwerpunkt Forschung
Fon: 040.361 226 43239
E-Mail schreiben
Dr. Oliver Zimmer
Wissenschaftlicher Mitarbeiter, Schwerpunkt Forschung
Fon: 040.361 226 43239
E-Mail schreiben
Oliver Zimmer completed his pharmacy studies (2nd state examination) at the University of Hamburg. He then completed his practical pharmaceutical training in the Regulatory Strategy department of Allergopharma GmbH & Co. KG. During his university studies, he pursued his research interest by working on molecular dynamic studies on nuclear transcription factors at the Institute of Pharmacy at the University of Hamburg.
After obtaining his licensure as a pharmacist, he was drawn to science. At the University of Regensburg's Institute of Pharmacy, he completed a dissertation on the influence of cell membrane morphology on the avidity of nanoparticulate drug carriers in Prof. Göpferich's working group. After completing his doctorate, Oliver joined Prof. Angela Relógio's research group at the Medical School Hamburg in September 2024.
In this group at the Institute of Systems Medicine, Oliver focuses on the development of models for the simulation of drug therapies, especially with regard to the integration of the latest findings in circadian medicine.
Oliver Zimmer began his teaching activities during his doctorate at the University of Regensburg. Here he was particularly involved in practical courses in pharmaceutical technology and supervised both undergraduate and graduate students. Oliver was also involved in the implementation of interdisciplinary practical courses. For example, he supervised practical modules in the field of bioanalytics as part of Master's degree programs. At MSH, he is involved as a tutor in the scientific work module.
Oliver Zimmer conducts interdisciplinary research focusing on the integration of pharmacokinetic/dynamic modeling with circadian processes. The aim of his work is to develop predictive models that enable the optimization of drug therapies based on the circadian data of individual patients. The aim is to maximize therapeutic efficacy while minimizing undesirable side effects as part of individualized treatment.